Vol. 6 No. 10 (2026): October
Reimbursement Reviews

Gilteritinib (Xospata)

decorative image of the issue cover

Published October 29, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses gilteritinib (Xospata), 40 mg, tablet, oral.
  • Indication: The treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.